Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Use of Indomethacin for mild and moderate Covid -19 patients A Randomized Control Trial

Rajan Ravichandran, Surapaneni Krishna Mohan, Suresh Kumar Sukumaran, Devakumar Kamaraj, Sumetha Suga Daivasuga, Samson Oliver Abraham Samuel Ravi, Sivakumar Vijayaraghavalu, Ramarathnam Krishna Kumar
doi: https://doi.org/10.1101/2021.07.24.21261007
Rajan Ravichandran
1Department of Nephrology, MIOT International, Chennai 600089, India and Adjunct Faculty, Indian Institute of Technology Madras (IITM), Chennai 600036, Tamil Nadu (TN), India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Surapaneni Krishna Mohan
2Departments of Biochemistry, Molecular Virology & Research, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suresh Kumar Sukumaran
3Department of General Medicine, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devakumar Kamaraj
4Departments of Pharmacology & Research, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sumetha Suga Daivasuga
5Departments of Microbiology & Molecular Virology, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samson Oliver Abraham Samuel Ravi
6Molbio Diagnostics Private Limited, Verna Industrial Estate, Verna, Goa - 403 722, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivakumar Vijayaraghavalu
7Narayana Translational Research and Incubation Center, Narayana Medical College, Nellore 524003, Andhra Pradesh, India and Adjunct Faculty, IITM, Chennai 600036, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramarathnam Krishna Kumar
8Department of Engineering Design, IITM, Chennai 600036, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rkkumar@iitm.ac.in
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Indomethacin has shown to be a broad spectrum anti-viral agent apart from it being a non-steroidal anti-inflammatory drug (NSAID). This randomized clinical trial in a hospital setting is to evaluate the efficacy and safety of this drug in RT-PCR positive Covid patients.

Materials and Methods RT-PCR positive Covid-19 patients, who gave the consent for the trial, were allotted to a control, or case, arm based on block randomization procedure. The control arm received the standard care consisting of paracetamol, ivermectin and other adjuvant therapy. The case arm had indomethacin instead of paracetamol, retaining the other medications. The endpoint was the development of hypoxia/desaturation. Secondary endpoints were time to become afebrile and time to resolution of cough and myalgia.

The results of 210 patients were available at this point, with 102 patients in the indomethacin arm and 108 in the paracetamol arm. The complete patient profile along with everyday clinical parameters were monitored. Blood chemistry at the time of admission and discharge were also carried out.

Results As no one required high-flow oxygen, desaturation with an SpO2 level of 93 and below was considered an important goal. In the indomethacin group, no one out of the 102 patients developed desaturation. On the other hand, 20 of the 108 patients in the paracetamol arm developed desaturation. Patients who received indomethacin also experienced more rapid symptomatic relief compared to those in the paracetamol arm, with most symptoms disappearing in half the time. A total of 56 patients out of 108 in the paracetamol arm had fever on the seventh day, while no one recorded fever in the indomethacin arm. No adverse event was reported in either arms. A fourteenth day follow up revealed that the paracetamol arm patients had several discomfort including myalgia, joint pain and tiredness while the indomethacin arm patients complained only of tiredness.

Conclusion Indomethacin is a safe and effective drug for the treatment of mild and moderate Covid-19 patients.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

CTRI Registration No CTRI/2021/05/033544

Funding Statement

Funding: Funding for this study was provided by Mr. Kris Gopalakrishnan, Alumnus of the Indian Institute of Technology Madras. He is also the Chairman of Axilor Ventures

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The approval for the study was given by the ethics committee of the Panimalar Medical College. The document no : PMCH&RI/IHEC/2021/051

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest The authors have no conflicts of interest to report.

  • Funding: Funding for this study was provided by Mr. Kris Gopalakrishnan, Alumnus of the Indian Institute of Technology Madras. He is also the Chairman of Axilor Ventures

Data Availability

All data are available and can be obtained with ethics committee clearance

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted July 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Use of Indomethacin for mild and moderate Covid -19 patients A Randomized Control Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Use of Indomethacin for mild and moderate Covid -19 patients A Randomized Control Trial
Rajan Ravichandran, Surapaneni Krishna Mohan, Suresh Kumar Sukumaran, Devakumar Kamaraj, Sumetha Suga Daivasuga, Samson Oliver Abraham Samuel Ravi, Sivakumar Vijayaraghavalu, Ramarathnam Krishna Kumar
medRxiv 2021.07.24.21261007; doi: https://doi.org/10.1101/2021.07.24.21261007
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Use of Indomethacin for mild and moderate Covid -19 patients A Randomized Control Trial
Rajan Ravichandran, Surapaneni Krishna Mohan, Suresh Kumar Sukumaran, Devakumar Kamaraj, Sumetha Suga Daivasuga, Samson Oliver Abraham Samuel Ravi, Sivakumar Vijayaraghavalu, Ramarathnam Krishna Kumar
medRxiv 2021.07.24.21261007; doi: https://doi.org/10.1101/2021.07.24.21261007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (414)
  • Anesthesia (90)
  • Cardiovascular Medicine (858)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8561)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1749)
  • Geriatric Medicine (167)
  • Health Economics (372)
  • Health Informatics (1242)
  • Health Policy (620)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10299)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (211)
  • Neurology (1677)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (450)
  • Oncology (928)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (113)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (252)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1768)
  • Public and Global Health (3837)
  • Radiology and Imaging (623)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (167)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)